MIDN

Overview

MIDN (Midnolin) is a gene on chromosome 19p13.3 implicated in a novel chromosomal inversion in translocation renal cell carcinoma (tRCC). Its fusion with SBNO2 was identified in a TFE3-fusion-negative tRCC case, expanding the spectrum of driver rearrangements in this tumor subtype.

Alterations observed in the corpus

• MIDN-SBNO2 fusion resulting from a novel chr19p13.3 inversion identified in a TFE3-fusion-negative tRCC (sample 14336T); drives high SBNO2 expression PMID:25401301

Cancer types (linked)

• tRCC: novel MIDN-SBNO2 fusion as an alternative driver in TFE3-fusion-negative cases PMID:25401301

Co-occurrence and mutual exclusivity

• MIDN-SBNO2 fusion occurs in TFE3-fusion-negative tRCC, suggesting mutual exclusivity with classical TFE3 translocations PMID:25401301

Therapeutic relevance

• No targeted therapies established; SBNO2 upregulation via fusion is hypothesized to modulate MiTF family members but functional consequences remain undemonstrated PMID:25401301

Open questions

• Whether SBNO2 modulates other MiTF family members downstream of the MIDN-SBNO2 fusion is hypothesized but not experimentally demonstrated PMID:25401301

Sources

• PMID:25401301

This page was processed by entity-page-writer on 2026-05-11.